Abstract:Ursolic acid (UA) is a natural product which has been shown to possess a wide range of pharmacological activities, in particular those with anticancer activity. In this study, 13 novel ursolic acid derivatives were designed and synthesized in an attempt to further improve compound potency. The structures of the newly synthesized compounds were confirmed using mass spectrometry, infrared spectroscopy, and (1) H NMR. The ability of the UA derivatives to inhibit cell growth was assayed against both various tumor cell lines and a non-pathogenic cell line, HELF. Analysis of theoretical toxicity risks for all derivatives was performed using OSIRIS and indicated that the majority of compounds would present moderate to low risks. Pharmacological results indicated that the majority of the derivatives were more potent growth inhibitors than UA. In particular, 5b demonstrated IC50 values ranging from 4.09 ± 0.27 to 7.78 ± 0.43 μm against 12 different tumor cell lines. Flow cytometry analysis indicated that 5b induced G0/G1 arrest in three of these cell lines. These results were validated by structural docking studies, which confirmed that UA could bind to cyclins D1 (Cyc D1) and cyclin-dependent kinases (CDK6), the key regulators of G0/G1 transition in cell cycle, while the piperazine moiety of 5b could bind with glucokinase (GK), glucose transporter 1 (GLUT1), and ATPase, which are the main proteins involved in cancer cell metabolism. Acridine orange/ethidium bromide staining confirmed that 5b was capable of inducing apoptosis and decreasing cell viability in a dose-dependent manner.

Screening of Ursolic Acid Analogs with HIF-1α and COX-2-Inhibiting Effects

Design, synthesis, and evaluation of novel ursolic acid derivatives as HIF-1α inhibitors with anticancer potential

Synthesis, Crystal Structures, Fluorescence and Xanthine Oxidase Inhibitory Activity of Pyrazole-Based 1,3,4-Oxadiazole Derivatives

New ursolic acid derivatives bearing 1,2,3-triazole moieties: design, synthesis and anti-inflammatory activity in vitro and in vivo

Synthesis And Biological Evaluation Of 3-Aryl-Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide Derivatives As Hypoxic Selective Anti-Tumor Agents

Synthesis and Biological Evaluation of 3-Aryl-quinoxaline-2-carbonitrile 1,4-Di-<em>N</em>-oxide Derivatives as Hypoxic Selective Anti-tumor Agents

Design, Synthesis, and Evaluation of the COX-2 Inhibitory Activities of New 1, 3-dihydro-2H-indolin-2-one Derivatives

Synthesis, Molecular Modeling and Biological Assessment of Aryloxymethyl 1,3,4-Thiadiazole and 1,2,4-Triazole-5-Thione Derivatives as Potential Cox Inhibitors

Synthesis and biological evaluation of ursolic acid derivatives containing an aminoguanidine moiety

Synthesis and Biological Evaluation of Isoaurone Derivatives as Anti‐inflammatory Agents

Design, synthesis, and biological evaluation of 1,5-diaryl-1,2,4-triazole derivatives as selective cyclooxygenase-2 inhibitors

Design, Synthesis and Biological Evaluation of Pyridine Acyl Sulfonamide Derivatives As Novel COX-2 Inhibitors

Design, synthesis, and hypoxia-inducible factor-1α inhibitory activity evaluation of panaxadiol derivatives containing a thiazole moiety

Synthesis, Molecular Modeling, and Biological Evaluation of Quinazoline Derivatives Containing the 1,3,4-Oxadiazole Scaffold As Novel Inhibitors of VEGFR2

Design, synthesis, biological evaluation and molecular modeling of dihydropyrazole sulfonamide derivatives as potential COX-1/COX-2 inhibitors.

Synthesis and Biological Evaluation of Novel Ursolic acid Derivatives as Potential Anticancer Prodrugs

Synthesis, crystallographic characterization, molecular docking and biological activity of isoquinoline derivatives

Design, synthesis and anti-inflammatory assessment of certain substituted 1,2,4-triazoles bearing tetrahydroisoquinoline scaffold as COX 1/2-inhibitors

Design, Synthesis and Biological Activities Evaluation of Novel Pterostilbene-urea Derivatives as Potential Anti- inflammatory Agents

Design, synthesis, evaluation and molecular modelling studies of some novel 5,6-diphenyl-1,2,4-triazin-3(2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: A hybrid pharmacophore approach

Design, Synthesis, and Biological Evaluation of Novel Nitrogen Heterocycle-Containing Ursolic Acid Analogs as Antitumor Agents